Treatment of aphasia by electrical stimulation and/or drug infusion
View Patent ↗Systems and methods are provided for applying electrical stimulation and/or introducing one or more stimulating drugs to the brain to treat or prevent aphasia, including through use of at least one system control unit (SCU) for controlling electrical pulses delivered via electrodes implanted in the brain and/or for producing drug infusion pulses to targeted areas in the brain.
1. A method of treating a patient with conductive aphasia caused by an abnormally functioning arcuate fasciculus that hinders communication between a Broca's area and a Wernicke's area of the patient's brain, comprising:
providing at least one System Control Unit (SCU) controllably connected to one or more electrodes and/or infusion outlets;
implanting the one or more electrodes and/or infusion outlets in or adjacent to the Wernicke's area;
measuring an attempted speech production of the patient and transmitting a corresponding signal to the SCU; and
activating the SCU in response to the transmitted signal to control delivery of a stimulus from the one or more electrodes and/or infusion outlets to the Wernicke's area to circumvent the communication role of the arcuate fasciculus, thereby treating or reducing an occurrence or severity of a symptom of the conductive aphasia.
2. The method of claim 1 , wherein the SCU is connected to or comprises at least one pump that is operably connected to the one or more infusion ports, and wherein the stimulus comprises stimulation via one or more drugs delivered from the one or more infusion ports through action of the pump.
3. The method of claim 2 , wherein the one or more drugs are configured to increase excitement of at least one area of the brain that exhibits chronic decreased activity and wherein the one or more drugs comprise at least one of excitatory neurotransmitters, excitatory neurotransmitter agonists, inhibitory neurotransmitter antagonists, agents that increase the level of an excitatory neurotransmitter, and agents that decrease the level of an inhibitory neurotransmitter.
4. The method of claim 3 , wherein the drug that increases excitement of at least one area of the brain that exhibits chronic decreased activity is selected from the group consisting of glutamate, dopamine, norepinephrine, epinephrine, acetylcholine, serotonin, glutamate receptor agonist, L-aspartic acid, N-methyl-D-aspartic acid (NMDA), bethanechol, norepinephrine, bicuculline, edrophonium, and mestinon.
5. The method of claim 2 , wherein the one or more drugs are configured to decrease excitement of at least one area of the brain that exhibits chronic increased activity and wherein the one or more drugs comprise at least one of inhibitory neurotransmitters, inhibitory neurotransmitter agonists, excitatory neurotransmitter antagonists, agents that increase the level of an inhibitory neurotransmitter, agents that decrease the level of an excitatory neurotransmitter, anesthetic agents, and analgesic medications.
6. The method of claim 5 , wherein drug that decreases excitement of at least one area of the brain that exhibits chronic increased activity is selected from the group consisting of gamma-aminobutyric acid, dopamine, glycine, midazolam, clonidine, muscimol, prazosin, metoprolol, atropine, benztropine, acetyicholinesterase, and Group II metabotropic glutamate receptor agonists.
7. The method of claim 1 , wherein one or more of the SCU comprises at least one microstimulator.
8. The method of claim 1 , wherein the stimulus is electrical stimulation delivered from the one or more electrodes.
9. The method of claim 1 , wherein one or more of the SCU control one or more stimulation parameters selected from the group consisting of: on/off patterns; pulsewidth; pulse amplitude; repetition rate or pulses per second (pps); and electrode configurations.
10. The method of claim 9 , wherein the electrode configurations are selected from the group consisting of: monopolar, bipolar, and tripolar.
11. The method of claim 1 , wherein the Broca's area and Wernicke's area are both normal.
12. The method of claim 1 , wherein the arcuate fasciculus has a lesion that prevents communication between the Broca's area and Wernicke's area.
13. The method of claim 1 , wherein the attempted speech production of the patient is measured via one or more sensors implanted within the patient.
14. The method of claim 13 , wherein the one or more sensors are implanted adjacent the Broca's area.